{"nctId":"NCT02607930","briefTitle":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","startDateStruct":{"date":"2015-11-13","type":"ACTUAL"},"conditions":["HIV-1 Infection"],"count":631,"armGroups":[{"label":"B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF","Drug: ABC/DTG/3TC Placebo"]},{"label":"ABC/DTG/3TC","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABC/DTG/3TC","Drug: B/F/TAF Placebo"]},{"label":"Open-label Phase B/F/TAF to B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]},{"label":"Open-label Phase ABC/DTG/3TC to B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]}],"interventions":[{"name":"ABC/DTG/3TC","otherNames":["Triumeq®"]},{"name":"B/F/TAF","otherNames":["GS-9883/F/TAF","Biktarvy®"]},{"name":"ABC/DTG/3TC Placebo","otherNames":[]},{"name":"B/F/TAF Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to screening\n* Plasma HIV-1 ribonucleic acid (RNA) levels ≥ 500 copies per milliliter (mL) at screening\n* Adequate renal function: Estimated glomerular filtration rate ≥ 50 milliliter per minute (mL/min) (≥ 0.83 milliliter per second \\[mL/sec\\]) according to the Cockcroft-Gault formula\n* Negative screening test for human leukocyte antigen (HLA) -B x 5701 allele provided by Gilead Sciences\n\nKey Exclusion Criteria:\n\n* An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening (refer to study protocol)\n* Decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal bleeding)\n* Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance\n* Females who are pregnant (as confirmed by positive serum pregnancy test)\n* Females who are breastfeeding\n* Chronic Hepatitis B Virus (HBV) infection\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"93.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null},{"groupId":"OG001","value":"89.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"84.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":null},{"groupId":"OG001","value":"87.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.4","spread":null},{"groupId":"OG001","value":"84.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null},{"groupId":"OG001","value":"82.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in log10 HIV-1 RNA at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.11","spread":"0.641"},{"groupId":"OG001","value":"-3.07","spread":"0.738"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in log10 HIV-1 RNA at Week 96","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":"0.643"},{"groupId":"OG001","value":"-3.10","spread":"0.705"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in log10 HIV-1 RNA at Week 144","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.11","spread":"0.639"},{"groupId":"OG001","value":"-3.10","spread":"0.681"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":"185.8"},{"groupId":"OG001","value":"228","spread":"188.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 96","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"287","spread":"206.9"},{"groupId":"OG001","value":"288","spread":"246.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 144","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":"224.9"},{"groupId":"OG001","value":"317","spread":"219.5"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hip BMD at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.802","spread":"2.3280"},{"groupId":"OG001","value":"-1.148","spread":"2.5126"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hip BMD at Week 96","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.128","spread":"2.7702"},{"groupId":"OG001","value":"-1.262","spread":"2.8524"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Hip BMD at Week 144","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.020","spread":"3.7638"},{"groupId":"OG001","value":"-1.291","spread":"3.1140"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Spine BMD at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.772","spread":"3.2228"},{"groupId":"OG001","value":"-0.552","spread":"3.0956"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Spine BMD at Week 96","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.705","spread":"3.8721"},{"groupId":"OG001","value":"-0.219","spread":"3.5159"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Spine BMD at Week 144","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.371","spread":"4.4369"},{"groupId":"OG001","value":"0.035","spread":"3.5182"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"99.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.2","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48 Open-Label","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":"242.8"},{"groupId":"OG001","value":"-4","spread":"202.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 96 Open-Label","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":"237.8"},{"groupId":"OG001","value":"-15","spread":"188.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":44,"n":314},"commonTop":["Upper respiratory tract infection","Syphilis","Nausea","Diarrhoea","Nasopharyngitis"]}}}